Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Synbalance Srl has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, showing separate examination paths.
CELSA, BENNETT M is the busiest examiner, with 1 pending matter. The pending workload is not concentrated with one examiner. Each response should reflect its specific art unit and examiner assignment.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CELSA, BENNETT M | 1 | 33.3% | +0.0% |
| ZINGARELLI, SANDRA | 1 | 6.7% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719160 | PROBIOTIC COMPOSITIONS AND THEIR USE IN MODULATING ALLERGY-TYPE INFLAMMATORY ACTIVITY | CELSA, BENNETT M | 20d |
| 18257267 | PROBIOTIC COMPOSITIONS AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF STRESS-RELATED CONDITIONS | ZINGARELLI, SANDRA | 36d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257267 | PROBIOTIC COMPOSITIONS AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF STRESS-RELATED CONDITIONS | ZINGARELLI, SANDRA | 36d |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719160 | PROBIOTIC COMPOSITIONS AND THEIR USE IN MODULATING ALLERGY-TYPE INFLAMMATORY ACTIVITY | CELSA, BENNETT M | 1651 | §103§112 | Final Rejection | 20d | Pending | Jun 12, 2024 |
| 18257267 | PROBIOTIC COMPOSITIONS AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF STRESS-RELATED CONDITIONS | ZINGARELLI, SANDRA | 1653 | §103 | Final Rejection | 36d | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSynbalance Srl has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bennett M Celsa has the most, with 1 of Synbalance Srl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
